ResearcherJohns Hopkins UniversityActive in the last 2 years
Linda Ye
Matched on ORCID iD 0000-0002-0353-4265; OpenAlex author ID A5102944562. Sources: OpenAlex.
Their work
- Papers
- 5 (first author 1, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 14
2020: 1 paper · 2021: 2 papers · 2022: none · 2023: 1 paper · 2024: none · 2025: 1 paper
Papers 5
- Editorial: To Beam, or Not to Beam-That Is the Question: Reflecting on the Role of Neoadjuvant Radiotherapy in Resectable Pancreatic Cancer. Co-author DOI 10.1245/s10434-025-18210-y↗
- Low dosage combination treatment with metformin and simvastatin inhibits obesity-promoted pancreatic cancer development in male KrasG12D mice. First author DOI 10.1038/s41598-023-43498-9↗
- Direct Effects of Lipopolysaccharide on Human Pancreatic Cancer Cells. Co-author DOI 10.1097/mpa.0000000000001790↗
- The Effect of Perioperative Blood Transfusion on Long-Term Survival Outcomes After Surgery for Pancreatic Ductal Adenocarcinoma: A Systematic Review. Co-author DOI 10.1097/mpa.0000000000001825↗
- Should All Patients With Pancreatic Cancer Receive Chemotherapy Before Surgery? Co-author DOI 10.1001/jamasurg.2020.2302↗
Closest collaborators
The 14 strongest of 14 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Oscar Joe Hines · 4 shared papers, 2020–2023 · strength 0.75
- Paper Should All Patients With Pancreatic Cancer Receive Chemotherapy Before Surgery? DOI 10.1001/jamasurg.2020.2302↗
- Paper The Effect of Perioperative Blood Transfusion on Long-Term Survival Outcomes After Surgery for Pancreatic Ductal Adenoc… DOI 10.1097/mpa.0000000000001825↗
- Paper Low dosage combination treatment with metformin and simvastatin inhibits obesity-promoted pancreatic cancer development… DOI 10.1038/s41598-023-43498-9↗
- Jin Peng He · 1 shared paper, 2025 · strength 0.42
- Marco Dal Molin · 1 shared paper, 2025 · strength 0.42
- Yaroslav Teper · 2 shared papers, 2021–2023 · strength 0.33
- Guido Eibl · 2 shared papers, 2021–2023 · strength 0.33
- Edward H. Livingston · 1 shared paper, 2021 · strength 0.19
- Aurelia Lugea · 1 shared paper, 2023 · strength 0.18
- James W. Sinnett‐Smith · 1 shared paper, 2023 · strength 0.18
- Richard T. Waldron · 1 shared paper, 2023 · strength 0.18
- Xiaoying Sun · 1 shared paper, 2023 · strength 0.18
- Stephen Jacob Pandol · 1 shared paper, 2023 · strength 0.18
- Enrique Rozengurt · 1 shared paper, 2023 · strength 0.18
- Soichiro Ako · 1 shared paper, 2021 · strength 0.15
- Roxanne L. Massoumi · 1 shared paper, 2021 · strength 0.15
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.